Vivien Häußler, Achim Berthele, Brigitte Wildemann, Clemens Warnke, Hayrettin Tumani, Corinna Trebst, Jan-Patrick Stellmann, Markus Krumbholz, Joachim Havla, Tania Kümpfel, Friedemann Paul, Ingo Kleiter, Sven Jarius, Judith Bellmann-Strobl, Florian Then Bergh, Luisa Klotz, Marius Ringelstein, Orhan Aktas, Katrin Giglhuber, Makbule Senel, Kerstin Hellwig, Ilya Ayzenberg, Martin W Hümmert, Klemens Ruprecht
Journal: Journal of neurology 2024;271(1):141-176
PMID: 37676297
This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.
© 2023. The Author(s).
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.